DSGN — Design Therapeutics Share News
0.000.00%
Last trade - 00:00- $656.48m
- $449.09m
U.S. RESEARCH ROUNDUP- Churchill Downs, Mirati Therapeutics, Vivint Smart Home
Brief: Design Therapeutics Reports Positive Data From Single-Ascending Dose Trial Of DT-216 For The Treatment Of Friedreich Ataxia And Portfolio Progress
Design Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Design Therapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview
RBC sees nod for Amylyx's ALS drug as a sign of FDA flexibility
Brief: Design Therapeutics Inc Reports Qtrly Loss Per Share $0.27
Design Therapeutics Inc expected to post a loss of 25 cents a share - Earnings Preview
Design Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
U.S. RESEARCH ROUNDUP- Applied Blockchain, Cheniere Energy, Roblox
Design Therapeutics Inc expected to post a loss of 22 cents a share - Earnings Preview
Brief: Design Therapeutics Inc Files For Mixed Shelf Of Up To $300 Mln
Brief: Design Therapeutics Completes Dosing In First Patient Cohort Of Phase 1 Trial Of DT-216 GeneTAC™ Molecule For The Treatment Of Friedreich Ataxia
Brief: Design Therapeutics Reports Pipeline And Business Progress And Fourth Quarter And Full Year 2021 Financial Results
Brief: Design Therapeutics Announces Preclinical Data Highlighting Novel Genetac™ Therapy For The Treatment Of Fuchs Endothelial Corneal Dystrophy To Be Presented At ARVO 2022
Brief: Design Therapeutics Announces FDA Clearance Of Investigational New Drug Application For First Genetac Molecule For Friedreich Ataxia
Brief: Design Therapeutics Appoints Jae Kim As Chief Medical Officer
Brief: Design Therapeutics Reports Pipeline Progress And Third Quarter 2021 Results
Brief: Design Therapeutics Announces Positive Preclinical Data Highlighting Disease-Modifying Potential Of Its Novel DM1 Genetacs As Treatment For Myotonic Dystrophy Type-1
Design Therapeutics Inc reports results for the quarter ended in June - Earnings Summary